Evidence map›Paper›PMID 36253358›Full record

ArticleCell death & disease2022

Bone marrow mesenchymal stem cell-derived exosomal miR-21a-5p alleviates renal fibrosis by attenuating glycolysis by targeting PFKM.

Shihao Xu, Yin Celeste Cheuk, Yichen Jia, Tian Chen, Juntao Chen, Yongsheng Luo, Yirui Cao, Jingjing Guo, Lijun Dong, Yi Zhang and 2 more

Abstract read
In one paragraph

Article in Cell death & disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shihao Xu *Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Yin Celeste Cheuk *Department of Urology, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Yichen Jia *Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Tian ChenDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Juntao ChenDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Yongsheng LuoDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Yirui CaoDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Jingjing GuoDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Lijun DongOperation Room, Shanghai Tenth People's Hospital, Tongji University, Shanghai, 200072, China.
Yi ZhangShanghai Key Laboratory of Organ Transplantation, Shanghai, 200032, China. yzhang_med@fudan.edu.cn.ORCID 0000-0003-0351-5184
Yi ShiShanghai Key Laboratory of Organ Transplantation, Shanghai, 200032, China. shi.yi@zs-hospital.sh.cn.
Ruiming RongDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. rong.ruiming@zs-hospital.sh.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal fibrosis is a common pathological feature and outcome of almost all chronic kidney diseases, and it is characterized by metabolic reprogramming toward aerobic glycolysis. Mesenchymal stem cell-derived exosomes (MSC-Exos) have been proposed as a promising therapeutic approach for renal fibrosis. In this study, we investigated the effect of MSC-Exos on glycolysis and the underlying mechanisms. We demonstrated that MSC-Exos significantly ameliorated unilateral ureter obstruction (UUO)-induced renal fibrosis by inhibiting glycolysis in tubular epithelial cells (TECs). miRNA sequencing showed that miR-21a-5p was highly enriched in MSC-Exos. Mechanistically, miR-21a-5p repressed the expression of phosphofructokinase muscle isoform (PFKM), a rate-limiting enzyme of glycolysis, thereby attenuating glycolysis in TECs. Additionally, knockdown of miR-21a-5p abolished the renoprotective effect of MSC-Exos. These findings revealed a novel role for MSC-Exos in the suppression of glycolysis, providing a new insight into the treatment of renal fibrosis.

Indexed as

ExosomesKidney DiseasesMesenchymal Stem CellsMicroRNAsPhosphofructokinase-1, Muscle TypeFibrosisGlycolysisHumansMusclesProtein IsoformsMicroRNAsMIRN21 microRNA, humanPFKM protein, humanPhosphofructokinase-1, Muscle TypeProtein Isoforms

Identifiers

PMID36253358
PMCPMC9576726

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.